In a report released on March 21, Shane Storey from Wilsons maintained a Buy rating on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), ...
MELBOURNE, Australia and INDIANAPOLIS, March 21, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S ...
GlobalData on MSN2d
MHRA approves trofolastat for prostate cancer diagnostic imagingTrofolastat is a prostate-specific membrane antigen-targeting agent cleared for use with Technetium-99m for cancerous lesion ...
Stockhead on MSN6d
Health Check: Opthea’s solvency in question after monumental phase III eye disease trial failureOne of two of Opthea's phase III trials for a common eye disease has failed to meet its objectives, casting doubts on the ...
The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...
Telix’s next-generation PSMA-PET imaging agent for prostate cancer, Gozellix receives US FDA approves: Melbourne, Australia Monday, March 24, 2025, 17:00 Hrs [IST] Telix, a biop ...
From Phil King’s Regal Partners to Russel Pillemer’s Pengana Capital, fund managers loved vision treatment hopeful Opthea.
Stockhead on MSN3d
Health Check: ASX ‘Magnificent Seven’ rides high amidst the US healthcare mayhemWhile the US biotechnology sector has swooned on concerns about new US healthcare policies, the ASX 'Magnificent Seven' has soared.
According to Telix Pharmaceuticals, the product has a longer shelf-life (up to 6 hours) and an extended distribution radius compared with other gallium-based products.
Increasing cancer prevalence, including prostate cancer and neuroendocrine tumors, advances in nuclear medicine in the field ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback